argenx stock falls 2.06 percent as VYVGART data arrive
Published on 09/30/2026 at 16:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx stock (ISIN NL0010832176) was trading at EUR 840.20 at Lang & Schwarz on September 30, 2026 at 4:04 p.m. CEST, down 2.06 percent versus the prior close of EUR 857.90. The company has put fresh VYVGART evidence and pipeline updates before investors at the AANEM and MGFA scientific meetings.
VYVGART data broaden treatment
According to argenx in its September 29, 2026 release, Phase 3 ADAPT OCULUS data showed ocular MG scores improving from -4.5 to -6.8 points in AChR antibody-positive patients after two additional VYVGART cycles. Triple-seronegative patients improved from -2.7 to -4.5 points.
The release also covered real-world evidence from more than 1,100 U.S. patients. Those treated within one year of diagnosis recorded a mean MG-ADL reduction of 4.7 points in the first three months, versus 3.5 points for patients treated more than three years after diagnosis.
Quarterly numbers set a high bar
MarketBeat reported on September 9, 2026 that argenx posted USD 1.54 billion in Q2 2026 revenue against USD 1.45 billion consensus. Adjusted earnings per share were USD 7.32, compared with USD 5.86 expected, a USD 1.46 beat.
The same report cited a 32.19 percent net margin for the quarter. Market capitalization stood at USD 59.5 billion on September 30, 2026, while the 52-week range was USD 661.85 to USD 1,072.75.
Analyst target stays above quote
MarketBeat said 24 analysts carried a Moderate Buy consensus on September 9, 2026, with 17 Buy ratings, two Strong Buy ratings and five Hold ratings. The average 12-month target was USD 1,158.61, leaving the analyst benchmark in a different currency from the EUR reference quote.
The current debate therefore combines commercial execution with clinical breadth. The September 29 data added evidence in ocular MG, antibody-negative generalized MG and CIDP, while empasiprubart and adimanebart extend the pipeline beyond the established VYVGART franchise.
Argenx stock falls in afternoon trade
At Lang & Schwarz, argenx stock was trading at EUR 840.20 on September 30, 2026 at 4:04 p.m. CEST, down 2.06 percent from the prior close of EUR 857.90 on September 29, 2026.
argenx stock facts
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Primary exchange: Nasdaq and Euronext Brussels
- Price Lang & Schwarz (as of September 30, 2026, 4:04 p.m. CEST): EUR 840.20
- Change versus prior close: minus 2.06 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 857.90
- Market capitalization: USD 59.5 billion (as of September 30, 2026)
- 52-week range: USD 661.85-1,072.75 (as of September 30, 2026)
- Sector / Industry: Healthcare / Biotechnology
